N=~510
contact details, please visit
the J&J Clinical Trial Finder
Key eligibility criteria†:
- MM diagnosis according to IMWG criteria
- ECOG PS 0–2
- Cohorts A and C: received ≥3 prior lines of therapy and have not been exposed to a CAR T-cell or T-cell redirection therapy
- Cohort B: received ≥3 prior lines of therapy and have been exposed to T-cell redirection therapy within 3 months
- Cohort D: received ≥3 prior lines of therapy and have not been exposed to T-cell redirection therapies
- Cohort E: received at least 1 PI, 1 IMiD, and 1 anti-CD38 monoclonal antibody and have not been exposed to T-cell redirection therapies
- No history of stroke or seizure within 6 months prior to treatment
Primary outcome:
- ORR
Secondary outcomes‡:
- DOR
- ≥VGPR
- ≥CR
- sCR
- TTR
- PFS
- OS
- MRD negativity
- AEs
- SAEs
- Change in HRQoL
*Only recruiting for Cohort E. †Not a complete list of inclusion and exclusion criteria. ‡Not a complete list of secondary outcomes.
Ab, antibody; AE, adverse event; CAR, chimeric antigen receptor; CD, cluster of differentiation; CR, complete response; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; GPRC5D, G protein–coupled receptor class C group 5 member D; HRQoL, health-related quality of life; IMiD, immunomodulatory drug; IMWG, International Myeloma Working Group; MM, multiple myeloma; MRD, minimal residual disease; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PI, proteosome inhibitor; SAE, serious adverse event; sCR, stringent complete response; SC, subcutaneous; TTR, time to response; VGPR, very good partial response.